title: Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer.
abstract: OBJECTIVE
  To evaluate the chemoradiotherapy for locally advanced pancreatic cancer utilizing low dose gemcitabine as a radiation sensitizer administered twice weekly.
  
  
  METHODS
  We performed a retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40 mg/m(2). After that, maintenance systemic chemotherapy with gemcitabine, at a dose of 1000 mg/m(2), was administered weekly for 3 wk with 1-wk rest until disease progression or unacceptable toxicity developed.
  
  
  RESULTS
  Eighteen patients with locally advanced unresectable pancreatic cancer were enrolled. Three of those patients could not continue with the therapy; one patient had interstitial pneumonia during radiation therapy and two other patients showed liver metastasis or peritoneal metastasis during an early stage of the therapy. The median survival was 15.0 mo and the overall 1-year survival rate was 60%, while the median progression-free survival was 8.0 mo. The subgroup which showed the reduction of tumor development, more than 50% showed a tendency for a better prognosis; however, other parameters including age, gender and performance status did not correlate with survival. The median survival of the groups that died of liver metastasis and peritoneal metastasis were 13.0 mo and 27.7 mo, respectively.
  
  
  CONCLUSIONS
  Chemoradiotherapy with low-dose gemcitabine administered twice weekly could be effective to patients with locally advanced pancreatic cancer; however, patients developing liver metastases had a worse prognosis. Another chemoradiotherapy strategy might be needed for those patients, such as administrating one or two cycles of chemotherapy initially, followed by chemoradiotherapy for the cases with no distant metastases.
authors.affiliation: Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. igaras@intmed3.med.kyushu-u.ac.jp
authors.forename: Hisato
authors.initials: H
authors.lastname: Igarashi
authors.forename: Tetsuhide
authors.initials: T
authors.lastname: Ito
authors.forename: Ken
authors.initials: K
authors.lastname: Kawabe
authors.forename: Terumasa
authors.initials: T
authors.lastname: Hisano
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Arita
authors.forename: Toyoma
authors.initials: T
authors.lastname: Kaku
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Takayanagi
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D012189:Retrospective Studies; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):785-91
references.pmid: 10837965
references.citation: Lancet Oncol. 2008 Feb;9(2):132-8
references.pmid: 18249033
references.citation: J Gastroenterol. 2006 Jan;41(1):70-6
references.pmid: 16501860
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3270-5
references.pmid: 12149301
references.citation: World J Gastroenterol. 2007 Jun 7;13(21):2945-51
references.pmid: 17589944
references.citation: Int J Pancreatol. 2001;29(1):9-18
references.pmid: 11560155
references.citation: Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):98-104
references.pmid: 12909221
references.citation: J Surg Oncol. 2002 Nov;81(3):138-43
references.pmid: 12407726
references.citation: J Clin Oncol. 2007 Jan 20;25(3):326-31
references.pmid: 17235048
references.citation: J Clin Oncol. 1997 Jun;15(6):2403-13
references.pmid: 9196156
references.citation: Int J Gastrointest Cancer. 2003;34(2-3):107-16
references.pmid: 15361643
references.citation: JAMA. 2007 Jan 17;297(3):267-77
references.pmid: 17227978
references.citation: Cancer. 1981 Oct 15;48(8):1705-10
references.pmid: 7284971
references.citation: Oncology (Williston Park). 1996 Sep;10(9 Suppl):18-22
references.pmid: 8884803
references.citation: Pancreas. 2008 Jan;36(1):e26-32
references.pmid: 18192876
references.citation: Ann Surg. 2003 Dec;238(6 Suppl):S132-44; discussion S145-7
references.pmid: 14703755
references.citation: Semin Oncol. 2007 Aug;34(4):335-46
references.pmid: 17674962
references.citation: Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):903-11
references.pmid: 10705012
references.citation: Oncology. 2005;68(4-6):493-9
references.pmid: 16020980
references.citation: Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1293-302
references.pmid: 11955742
references.citation: Br J Cancer. 2004 Aug 16;91(4):673-7
references.pmid: 15226765
references.citation: J Natl Cancer Inst. 1988 Jul 20;80(10):751-5
references.pmid: 2898536
references.citation: J Clin Oncol. 1999 Jul;17(7):2208-12
references.pmid: 10561277
references.citation: JAMA. 2008 Mar 5;299(9):1019-26
references.pmid: 18319412
references.citation: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1325-30
references.pmid: 15993549